Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 262

Results For "CRO"

4631 News Found

Hikal announces USFDA audit with zero observations
Drug Approval | May 16, 2023

Hikal announces USFDA audit with zero observations

This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites


Mandaviya addresses the G7 Health Ministerial Meeting on health innovation
Policy | May 16, 2023

Mandaviya addresses the G7 Health Ministerial Meeting on health innovation

The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries


AiMeD welcomes Govt’s for assistance to medical devices clusters
Policy | May 16, 2023

AiMeD welcomes Govt’s for assistance to medical devices clusters

The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive


Advanced Enzyme Technologies posts Q4 FY23 consolidated PAT up at Rs. 32.12 Cr
News | May 15, 2023

Advanced Enzyme Technologies posts Q4 FY23 consolidated PAT up at Rs. 32.12 Cr

The company has reported total income of Rs. 149.78 crores during the period ended March 31, 2023


Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute
News | May 15, 2023

Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute

Dr. Reddy's Laboratories has been issued a Form 483 with four observations


Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr
News | May 13, 2023

Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr

Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023


Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr
News | May 13, 2023

Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr

Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023


Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
News | May 13, 2023

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023


Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr
News | May 12, 2023

Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr

The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023


Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr
News | May 11, 2023

Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr

The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023